Evaluation of a Novel Tumor Vaccine in Dogs with Hemangiosarcoma

Abstract

We conclude that an allogeneic tumor lysate vaccine is safe in dogs with HSA and can elicit humoral immune responses in dogs that are receiving concurrent doxorubicin chemotherapy.